Skip to content

Total debt at other companies

Xencor logo
XencorXNCR
$175.16M-21.2%
Vor Biopharma logo
Vor BiopharmaVOR
$2.94M-90.5%
Johnson & Johnson logo
Johnson & JohnsonJNJ
Amgen logo
AmgenAMGN
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
AbbVie logo
AbbVieABBV

Other financials

Income statement

See full
Revenue$3.7M
Operating income-$34.2M+2.0%
Net income-$24.4M-3.6%
EPS (diluted)-$0.39-2.6%

Balance sheet

See full
Cash & equivalents$51.8M-29.7%
Total equity$941.5M-7.0%
Total assets$1.0B-2.1%

Cash flow

See full
Operating cash flow-$12.3M+27.5%
CapEx$273.0K-26.4%
Free cash flow-$12.6M+27.5%

Valuation

See full
Market cap$892.81M-36.1%
Enterprise value$862.55M-35.9%
P/S65×-84.6×

Profitability

See full
Operating margin-1,143.1%-65.1pp
Net margin-833.6%+0.9pp
FCF margin-571.6%+98.3pp

Returns & leverage

See full
Return on equity-11.7%+4.1pp
Debt / equity0.0×
Current ratio17×-41.5×

Where this comes from

Computed from long term debt + current portion long term debt + short term borrowings + operating lease liabilities + finance lease liabilities + financing obligations: $21.57M.

The official record: Janux Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Janux Therapeutics's total debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Janux Therapeutics's total debt?
Janux Therapeutics (JANX) reported total debt of $21.57M in Q1 2026.
How has Janux Therapeutics's total debt changed year-over-year?
Janux Therapeutics's total debt decreased by 4.6% year-over-year, from $22.61M to $21.57M.
What is the long-term trend for Janux Therapeutics's total debt?
Over 4 years (2021 to 2025), Janux Therapeutics's total debt has grown at a 226.8% compound annual growth rate (CAGR), from $194K to $22.14M.
What does total debt mean?
Total debt represents the aggregate sum of all interest-bearing financial obligations, including short-term borrowings, the current portion of long-term debt, and long-term debt instruments. It also encompasses capitalized lease liabilities and other debt-like financing arrangements that require fixed repayment schedules. This metric serves as a comprehensive indicator of a company's total financial leverage and its reliance on external capital providers.